
Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Melbourne (Australia) – 3 May 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company's rapid commercial growth.

Dr. David Cade, who has served as Telix's Chief Business Officer and Head of Investor Relations since joining Telix in 2019, has been appointed President of Telix APAC. In this role, David will lead Telix's commercial activities across the Asia-Pacific region, including Telix's anticipated approval of Illuccix[®] in Australia and other regional territories. Mr. Jonathan Barlow, previously Telix's General Counsel will take an expanded executive role of Chief Business Development Officer and Group General Counsel and will be responsible for leading Telix's business development and legal functions globally. Telix has additionally recruited a Senior Vice President of Investor Relations and Corporate Communications, with a planned commencement date of early July.

Dr. Tracey Brown, who joined Telix in February 2020, has been appointed Global Senior Vice President of Product Portfolio Management. Dr. Brown will be responsible for driving the development of Telix's broad pipeline from early development through to commercialization. Dr. Michael Wheatcroft, who has served as Telix's Director of R&D since the inception of the company, has been promoted to the executive role of Chief Scientist. Dr. Wheatcroft will be responsible for Telix's research and innovation (R&I) programs globally, reflective of Telix's strong portfolio development in key areas such as Targeted Alpha Therapy.

As announced today, Mr. Richard Valeix has joined Telix as President Europe, Middle East and Africa (EMEA)¹, succeeding Mr. Ludovic Wouters who has served as Interim President of Telix EMEA for the past 15 months. Mr. Wouters will remain a key executive member of the European business development team.

Telix Chief Executive Officer Dr. Christian Behrenbruch stated, "These appointments reflect a significant restructuring of the business that is designed to support the transition to a commercial stage company. I would like to particularly recognise David Cade's outstanding contribution to the business and my support of his transition to the APAC leadership role. I'd also like to personally thank Ludo Wouters for his excellent leadership through a period of significant growth in the European team and the pivotal role Ludo has played in the recruitment of Richard to the EU team."

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and [LinkedIn](#).

Telix's lead investigational product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,² and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).³ Telix is also progressing marketing authorisation applications for

¹ Separate ASX disclosure 3/05/20.

² ASX disclosure 24/11/20.

³ ASX disclosure 14/04/21.

Illuccix® in the European Union⁴ and Canada.⁵ None of Telix's products have received a marketing authorisation in any jurisdiction.

Telix Corporate Contact

Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
Managing Director and CEO
Email: chris.behrenbruch@telixpharma.com

Telix Investor Relations

Dr. David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

⁴ ASX disclosure 1/05/20.

⁵ ASX disclosure 16/12/20.